Galectin Therapeutics earnings release, August 14, 2026

Galectin Therapeutics Inc (GALT) · Form 8-K, Item 2.02 · Filed · SEC filing

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc.

(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.

“We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path forward. We are working diligently and expect to submit the registrational Phase 3 protocol in the third quarter,” said Joel Lewis, Chief Executive Officer and

President of Galectin Therapeutics.

Mr. Lewis continued, “the strength of our NAVIGATE trial dataset was further validated and continued to gain momentum within the scientific community. New analyses were presented at EASL and the results of the trial and our novel central endoscopy review process were published in

Hepatology and

Gastro Hep Advances, respectively. Also in June 2026, we hosted an advisory committee meeting with several leading key opinion leaders at the inaugural SOLAR conference.

Finally, the recent issuance of common stock converting approximately $105.8 million in debt and accrued interest from our chairman, Mr. Uihlein, significantly enhanced our capital structure by strengthening the balance sheet. We will share additional updates when they become available”.¹

Belapectin Program Highlights

Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of Metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

MASH Cirrhosis²³

Q2 2026 and Recent Corporate Highlights

Upcoming Catalysts

Q2 2026 Financial Highlights⁴

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.⁵

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, — Condensed Consolidated Statements of Operations

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Operating expenses:Research and development2,1353,261
Operating expenses:General and administrative1,8471,364
Operating expenses:Total operating expenses3,9824,625
Operating expenses:Total operating loss-3,982-4,625
Other income (expense):Interest income2826
Other income (expense):Interest expense-2,004-1,826
Other income (expense):Change in fair value of derivatives-3,155-1,096
Other income (expense):Total other income-5,131-2,896
Other income (expense):Net loss-9,113-7,521
Other income (expense):Preferred stock dividends-62-63
Other income (expense):Net loss applicable to common stock-9,175-7,584
Other income (expense):Basic and diluted net loss per share-0.14-0.12
Other income (expense):Shares used in computing basic and diluted net loss per share65,87563,447

Balance Sheet

June 30, 2026 — Condensed Consolidated Balance Sheet Data (in thousands)

June 30, 2026December 31, 2025
Cash and cash equivalents13,26917,720
Total assets14,82619,532
Total current liabilities151,6198,030
Total liabilities151,678145,727
Total redeemable, convertible preferred stock1,7231,723
Total stockholders’ deficit-138,575-127,918
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year... (truncated)ilings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.⁶

Company Contact:

Jack Callicutt, Chief Financial Officer

(678) 620-3186 ir@galectintherapeutics.com

Investors Relations Contacts:

Kevin Gardner kgardner@lifesciadvisors.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin

Therapeutics’ galectin-3 inhibitor belapectin.⁷

Condensed Consolidated Statements of Operations

Condensed Consolidated Balance Sheet Data

# # #⁸

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.